Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 04/29 10:01:12 pm
54.84 USD   -1.61%
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue
04/28 MERCK : Christina Applegate and Merck Urge Insomnia Sufferers to Lea..
04/28DJAbbVie to Buy Cancer-Drug Maker for $5.8 Billion
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at tapan.panchal@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
04/28DJGilead Reports Drop in Hepatitis C Drug Revenue
04/28 MERCK : Montana State offering live stream of vaccine expert panel
04/28 NEW FINDINGS FROM MERCK & COMPANY IN : Drug...
04/28 MERCK : Christina Applegate and Merck Urge Insomnia Sufferers to Learn “Wh..
04/28 MERCK : MSD se joint à la campagne « Comblons les lacunes sur la vaccination » e..
04/28DJAbbVie to Buy Cancer-Drug Maker for $5.8 Billion
04/28 MERCK : Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They..
04/28 MERCK : MSD Joins Campaign to 'Close the Immunization Gap'and "Stay Polio Free" ..
04/28 MERCK : MSD Joins Campaign to ‘Close the Immunization Gap’and &ldquo..
04/26 NewLink Genetics Awarded $21.6 Million Contract Option by BARDA for Ebola Vac..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials